The Imaging Response Assessment Team (IRAT) is a shared resource providing image-based tumor metrics for cancer research, as one of a national consortium of cancer center IRATs. The IRAT serves as a key component of investigator-initiated, cooperative group and industry-sponsored clinical trials at Moffitt, providing quantitative size-based measurements of tumor response. Year-to-year increases in the volume of service have generated the need for a cost center to support and institutionalize the Moffitt IRAT. The present proposal seeks to expand the capabilities and scope of this IRAT to support the infrastructure necessary for investigator-initiated studies at Moffitt.
The specific aims for the current effort are to support the IRAT infrastructure, which is used to: 1) Maintain the current quality of reported quantitative data and rapid response time;2) Expand the quantitative nature of reporting through more detailed image analysis;3) Coordinate acquisition and analysis of radiological images in support of clinical trials;4) Consult in clinical trials protocol submission;5) Review clinical trials in Scientific Review Committee;6) Provide pilot data for grant submissions;7) Assist in development of non-traditional imaging endpoints for response assessment, including participation in ACRIN and COG trials;and 8) Educate and reach out to Moffitt oncologists and investigators to increase awareness of new horizons in cancer imaging. These achievements are critical to accommodate the increasing complexity and importance of imaging biomarkers in response assessment, as the limitations and inadequacies of conventional metrics are recognized. An expansion of IRAT personnel is an immediate need to realize these goals. In 2009, 169 clinical trials with a primary imaging endpoint to assess tumor response were active, with the majority originating from the Experimental Therapeutics program, followed by Immunology. Of these, 71 were investigator-initiated, non-Industrial Moffitt or cooperative trials, and 94 had new patient accrual in 2009. These clinical trials spanned the breadth of Oncology Groups at Moffitt. The Core requests CCSG support of $153,973 which is 39% of its operational budget.
The IRAT adds value to the CC mission by streamlining the process of integrating imaging into trials and providing QA/QC throughout the process, especially for trials not initiated by radiologists. Developing an infrastructure for the IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analysis, and novel biomarkers.
|Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75|
|Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585|
|Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506|
|Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350|
|Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149|
|Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88|
|Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556|
Showing the most recent 10 out of 1254 publications